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httpcense.Abstract Background: Approximately 75% of patients with non-small cell lung cancer (NSCLC)
present with locally advanced or metastatic disease which renders them inoperable and virtually
incurable. Whene the aim of treatment is palliation, radiotherapy and bronchotherapeutic proce-
dures are often recommended.
Aim of the work: To evaluate the outcome of endobronchial electrocautery and or external beam
radiotherapy (XRT) in the palliative treatment of patients with inoperable non-small cell lung cancer.
Patient and methods: 40 patients with unresectable stage IIIA and IIIB NSCLC, 33 males and 7
females, their mean age of 60.82 ± 6.23 years were recruited in the study. Eligible patients were ran-
domly classiﬁed into 3 groups: Group I: included 11 patients who received combined external irradi-
ation (XRT) with end bronchial electro cautery, Group II: included 11 patients who received end
bronchial electrocautery without external irradiation XRT, Group III: including 18 patients who
received external palliative irradiation alone. Evaluation of chest symptoms, chest CT, PFTs, ABGs
and quality of life outcomes were done before the interventional bronchoscopy and XRT therapies
then one week and one month after the end of treatment.3595477.
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174 S.M. Shehata et al.Results: As regards improvement of endobronchial symptoms; one week after completion of treat-
ment, Group III patients was signiﬁcantly lesser thanGroups I and II and one month after treatment,
there was no signiﬁcant difference between all patient groups except in cough which was in Group III
of lesser improvement than Groups I and II. As regards patients who had atelectasis before starting
treatment: Group I showed 100% disappearance of atelectasis either complete or partial one month
after completion of treatment whileGroup II showed 77.77%disappearance of atelectasis either com-
plete or partial and ﬁnally Group III showed 64.29% disappearance of atelectasis either complete or
partial. As regards changes in both FEV1% and FVC%; all patient groups showed signiﬁcant differ-
ences pretreatment and one month after completion of treatment and Group I patients was signiﬁ-
cantly different than patients of both Groups II & III.
Conclusions: The replacement of external radiation with bronchoscopic therapy may not be a rec-
ommended option, but its addition to XRT may be a relatively simple method of augmenting the
symptom palliative effect, providing higher response rates for re-expansion of collapsed lung and
reducing endobronchial obstruction endoscopically.
ª 2013 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis. Open access under CC BY-NC-ND license.Introduction
Almost 30% of lung cancer patients at present have thoracic
symptoms which may only be caused by the endobronchial
component of their disease such as cough, haemoptysis,
breathlessness and obstructive pneumonitis. Best palliative
therapy is usually provided by external irradiation, with or
without chemotherapy. In an emergency, however, or if relapse
occurs after external irradiation or prior resection, endoscopic
management may be more effective. When the main compo-
nent of the airway obstruction is endoluminal, endoscopic
disobliteration provides immediate and safe relief of symp-
toms. This may be achieved by various techniques including,
lasers, argon plasma, electrocautery, cryo-therapy; photody-
namic therapy and brachytherapy [1].
With increasing numbers of lung cancer patients, there was
increased need for sophisticated interventions in these patients
and expanding the role of Chest Department, Zagazig Univer-
sity in its surrounding environment. Intervention bronchos-
copy unit with APC and Electrocautery was established on
2008 at chest Department Zagazig University Hospitals.
The aim of this work was to evaluate the outcome of endo-
bronchial electrocautery and or external beam radiotherapy in
the palliative treatment of patients with inoperable non-small
cell lung cancer.
Patients and methods
This study was conducted at the Chest Department (Bronchos-
copy Unit) and Clinical Oncology Department of Zagazig Uni-
versity Hospitals during the period from June 2008 to June
2011. 40 patients with unresectable stage IIIA and IIIB
NSCLC, 33 males and 7 females, their mean age of
60.82 ± 6.23 years were included in the study. Patients gave
their signed written consent after detailed explanation of the
protocol of the study. All the included patients had a diag-
nosed unresectable NSCLC with endobronchial tumor in
either main or lobar bronchi.
Eligible patients were randomly classiﬁed into 3 groups:
 Group I: included 11 patients who received combined exter-
nal irradiation (XRT) with endobronchial electrocautery. Group II: included 11 patients who received endobronchial
electrocautery without XRT.
 Group III: including 18 patients who received external pal-
liative irradiation alone.
Inclusion criteria
To be eligible for the study, patients had to have:
(1) Unresectable endobronchial tumour when its main com-
ponent is endoluminal, present in the proximal main or
lobar bronchi, proved to be NSCLC by histopatholo-
gical examination of stage IIIA or IIIB [2].
(2) World Health Organization performance status of 0–2.
(3) No prior chemotherapy or surgery or radiotherapy.
All patients were considered ﬁt for palliative radiotherapy
when they had stage III disease which was too extensive for
radical irradiation on the basis of either [3]: A primary tu-
mor larger than 6 cm or the presence of more than a single
mediastinal node with a minimal diameter of 10 mm in the
short axis.
Patients were considered ﬁt for therapeutic bronchoscopy if
they had the following criteria [4]:
(1) Symptoms were related primarily to airway obstruction
(cough, dyspnea, hemoptysis and obstructive
pneumonia).
(2) The tumor was located within the lumen of the airway.
(3) The margins between tumor and normal airway were
identiﬁable.
Exclusion criteria
Operable tumors without any contraindications to surgery,
presence of severe coagulation defect, orthopneic patient with
severe respiratory distress, patients with extensive myocardial
ischaemia in ECG or patients with cardiac arrhythmias were
excluded from the study.
All patients were submitted to:
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Figure 1 Cough score response rate.
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Figure 2 Dyspnea score response rate.
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associated illness.
(2) Full clinical examination: general and local chest
examination.
(3) Postero-anterior and lateral chest radiography.
(4) CT scan of the chest.
(5) Diagnostic ﬁberoptic bronchoscopy.
(6) Lung function tests were performed by using computer-
ized pulmonary function apparatus (ZAN 100, comput-
erized pulmonary function apparatus).
(7) XRT delivered as the followings: the target volume was
irradiated with 3 Gy per fraction (ﬁve times a week) up
to a total dose of 30 Gy (100%) without correction for
lung tissue density.
(8) Interventional bronchoscopic electrocautery was per-
formed under general or local anesthesia. The ﬂexible
bronchoscopy was either passed directly or via an endo-
tracheal tube. General anesthesia technique for interven-
tional bronchoscopy is a total intravenous anesthesia,
consisting of hypnotic action and analgesia. Endotra-
cheal tube was inserted. FOB was inserted via endotra-
cheal tube and ventilation was assisted, controlled
(IPPV) or manual by hand bag. Intra-operative moni-
toring included continuous pulse oxymetry, electrocardi-
ography, and intermittent noninvasive measurement of
blood pressure were performed. With the electrocautery,
the monoplar probe was pressed against the tumor base
and applying 20–40 W of energy until sufﬁcient blanch-
ing was apparent. Inspired oxygen concentrations were
kept at 30% if possible. The pulsed mode and low
inspired oxygen concentrations were chosen to minimize
the risk of unintentional penetrating injury or airway
ﬁre. Coagulated or vaporized tissues were removed
mechanically or with suction. In the cases of bulky
tumor, electrocautery were used to coagulate the tumor
base to shut off vascular structures and to reduce the
risk of bleeding when tumor tissue was mechanically
removed. Retreatment sessions continued until >75%
reopening of the normal airway lumen had been
achieved.
(9) Symptoms were recorded and scored before treatment
then one week and one month after treatment comple-
tion using the Speiser symptom score [5].
(10) The primary endpoints were symptom response; symp-
tom response for each of the four measured symptoms
was documented.
(11) After completion of treatment all patients were re-exam-
ined by bronchoscopy one month after treatment com-
pletion for evaluation of endobronchial response. The
extent of obstruction using endoscopic criteria before
and after treatment was scored using the obstruction
score described by Speiser and Spratling.
(12) Deﬁnitive re-expansion of atelectasis or post-obstructive
pneumonia was assessed one and four weeks after the
end of the entire course of treatment by means of PFTs,
Chest radiographs and CT scan of the chest
(13) Acute and late pulmonary and esophageal toxicity were
recorded according to the Radiation Therapy Oncology
Group (RTOG) [6].
(14) Quality of life assessment using the EORTC QLQ-C30
Version 3 questionnaires before treatment and at one
week and one month following treatment [7,8].Statistical analysis
The demographic, clinical, radiological, physiological and
pathological data gathered together with the patients’ outcome
were tabulated and statistically analyzed and coded, entered
and checked to an Epi-info ﬁle using Epi-info version 10 com-
puter packages. Data were summarized using; the arithmetic
mean as an average describing the central tendency of observa-
tions, the standard deviation (S.D.) as a measure of dispersion
of the results around the mean, the number of observations for
each variable studied (NO).
The Chi-square test (v2), comparison of means: ANOVA
and multiple comparison tests (LSD and paired t-test): For
all the above-mentioned statistical tests, the threshold of signif-
icance is ﬁxed at the 5% level (p-value), a p-value P0.05 indi-
cates non-signiﬁcant results, a p-value <0.05 indicates
signiﬁcant results, a p-value <0.01 indicates high signiﬁcant
results, and a p-value <0.001 indicates very high signiﬁcant
results.
Results
One week after treatment, Group III was signiﬁcantly lesser
than Groups I and II as regards improvement of all endobron-
chial symptoms (cough, dyspnea, haemoptysis and obstructive
pneumonia) (see Figs. 1–4).
One month after treatment, Group III was signiﬁcantly les-
ser than Groups I and II as regards improvement of cough.
While, there was no signiﬁcant difference between all patient
groups as regards improvement of other endobronchial
symptoms.
Pre-treatment and one month after completion of treat-
ment, Group I and III showed signiﬁcant difference in mean
obstruction scores of lobar bronchi only, while Group II
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Figure 4 Fever score response rate.
176 S.M. Shehata et al.showed signiﬁcant difference in mean obstruction scores of
main bronchi only.
As regards patients with atelectasis before treatment: Group
I showed 100% disappearance of atelectasis either complete or
partial after treatment. Group II showed 77.77% disappear-
ance of atelectasis either complete or partial and 22.23% per-
sistence of atelectasis after treatment. Group III showed
64.29% disappearance of atelectasis either complete or partial,
21.4% persistence of atelectasis and 14.29% progression of
atelectasis after treatment. As regards patients without atelecta-
sis before treatment: Group I showed 100% prevention of ate-
lectasis after treatment. Group II showed 50% prevention of
atelectasis after treatment. Group III showed 75% prevention
of atelectasis after treatment (see Fig. 5).
Group I was signiﬁcantly different than Groups II and III
as regards changes in PaO2. One week and one month after
completion of treatment (see Figs. 6–8).
Group II was signiﬁcantly different than Groups I and III
as regards absence of post treatment complications. There was
no signiﬁcant difference between patient Groups I and III as
regards post treatment complications (see Fig. 9).
One week after completion of treatment:
Group III was signiﬁcantly different than Groups I and II
as regards global health status and (physical, role) func-
tional scales.45.45%
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Figure 5 Radiological assesment ‘‘one month post treatment’’.There was no signiﬁcant difference between all patient
groups as regards other functional scales.
Group I showed signiﬁcant difference as regards changes in
global health status and (physical, role, emotional) func-
tional scales, pre-treatment and one week after completion
of treatment.
Group II showed signiﬁcant difference as regards changes
in global health status and (physical, role, emotional and
cognitive) functional scales, pre-treatment and one week
after completion of treatment.
Outcome of endobronchial electrocautery versus external beam radiotherapy 177Group III showed signiﬁcant difference as regards changes
in (emotional and cognitive) functional scales, pre-treat-
ment and one week after completion of treatment.
One month after completion of treatment:
Group III was signiﬁcantly different than Groups I and II
as regards changes in physical functional scales only.
There was no signiﬁcant difference between all patient
groups as regards other Functional scales and global health
status.
Group I showed signiﬁcant difference as regards changes in
global health status and (physical, role, emotional) func-
tional scales, pre-treatment and one month after comple-
tion of treatment.
Group II showed signiﬁcant difference as regards changes
in global health status and (physical, role, emotional and
cognitive) functional scales, pre-treatment and one month
after completion of treatment.
Group III showed signiﬁcant difference as regards changes
in global health status and (physical, role, emotional and
cognitive) functional scales, pre-treatment and one month
after completion of treatment.
Discussion
The current study included 40 patients with unresectable stage
III NSCLC referred to Chest and Clinical Oncology
Departments, Zagazig University Hospitals, during the period
from June 2008 to June 2011. Patients were divided into 3
groups: The ﬁrst group (Group I) received both palliative
radiotherapy and electrocautary the second group (Group II)
received electrocautary alone and the third (Group III) re-
ceived palliative radiotherapy alone.Table 1 Comparison between different patient groups according t
completion of treatment.
Presenting symptoms Group I (No. of improved
patients/no of patients
having symptoms)
Cough No. (%)
Patients having symptom ‘‘pre-treatment’’ 11/11(100%)
Post-one week 10/11(90.9%)
Post-one month 10/11(90.9%)
Dyspnea No. (%)
Patients having symptom ‘‘pre-treatment’’ 10/11(90.9%)
Post-one week 8/10 (80%)
Post-one month 9/10 (90%)
Haemoptysis No. (%)
Patients having symptom ‘‘pre-treatment’’ 9/11(81.8%)
Post-one week 9/9(100%)
Post-one month 9/9 (100%)
Manifestations of obstructive pneumonia No. (%)
Patients having symptom ‘‘pre-treatment’’ 8/11 (72.7%)
Post-one week 6/8 (75%)
Post-one month 7/8 (87.5%)
a Means Group III was signiﬁcantly different than Groups I and II.In the present study, the mean ages of patients were 60.82,
62.55 and 60.72 years in Groups I, II and III respectively. As
regard the histopathological subtypes, Squamous cell carci-
noma was the commonest pathologic subtype among the stud-
ied patients groups, followed by adenocarcinoma then large
cell carcinoma.
The number of bronchoscopic sessions in patient Groups (I
& II) ranged from 1–4 sessions. As regards symptom response
rates Table 1 demonstrated that one week after completion of
treatment, there was an improvement in all the four symptoms
assessed in the three groups of patients. But, Group III was
signiﬁcantly lesser than Groups I and II as regards the overall
response rate of the four presenting symptoms. The therapeu-
tic bronchoscopic techniques electrocautary provided
signiﬁcant immediate relief of all endobronchial symptoms in
the majority of patients [9]. While XRT provided a delayed
relief of symptoms, it needed at least four weeks to allow
enough time for acute morbidity to subside and the majority
of responses to be evident [10].
One month after completion of treatment, the overall re-
sponse rate of cough in Group III was signiﬁcantly lesser than
in Groups I and II. While, there was no signiﬁcant difference
between the three patient groups as regards improvement in
dyspnea, hemoptysis and obstructive pneumonia. In our
patient groups, the addition of bronchoscopic electrocautary
to palliative external radiation appeared to provide a great
beneﬁt in symptom response rates, especially for haemoptysis.
Our results agreed with the following studies: Kvale et al.
[9] stated that immediate relief of dyspnea can be achieved with
electrocautery in 55–75% of patients. Crosta et al. [1] observed
an immediate and substantial subjective improvement consist-
ing in the complete regression of bleeding, obstructive infec-
tious complications and dyspnea. On the other hand, the
following studies demonstrated less response rate of symptom
improvement: Hosni et al. [11] demonstrated thato symptom score response rates one week and one month after
Group II (No. of improved
patients /no of patients
having symptoms)
Group III (No. of improved
patients/no of patients
having symptoms)
P value
11/11(100%) 18/18(100%) >0.05
10/11(90.9%) 6/18(33.3%)a <0.001
10/11(90.9%) 10/18(55.56%)***(c) <0.05
11/11(100%) 18/18(100%) >0.05
8/11 (72.7%) 5/18(27.28%)a <0.01
8/11 (72.7%) 10/18(55.56%) >0.05
8/11 (72.7%) 11/18(61.2%) >0.05
7/8 (87.5%) 3/11(27.27%)a <0.001
7/8 (87.5%) 8/11(72.73%) >0.05
9/11(81.8%) 11/18(61.2%) >0.05
6/9(66.67%) 2/11(18.18%)a <0.05
6/9(66.67%) 5/11(45.45%) >0.05
Table 2 Comparison between different patient groups according to obstruction scores pre-treatment and one month after completion
of treatment.
Site of obstruction Group I Group II Group III P value
No of Pat. Mean ± SD No of Pat. Mean ± SD No of Pat. Mean ± SD
Main bronchi
Pre-treatment 2 6 ± 0.0 4 5.25 ± 1.5 4 3 ± 0.0a <0.05
Post-treatment 2 3 ± 0.0 4 2.5 ± 1.0 4 4.5 ± 1.73 >0.05
P value Not computed <0.01 >0.05
Lobar bronchi
Pre-treatment 9 2 ± 0.0 7 1.71 ± 0.49b 14 2 ± 0.0 <0.05
Post-treatment 9 0.22 ± 0.44 7 0.86 ± 1.07 14 0.64 ± 0.63 >0.05
P value <0.001 >0.05 <0.001
a Means Group III was signiﬁcantly different than Groups I and II.
b Means Group II was signiﬁcantly different than Groups I and III.
Table 3 Radiological assessment as regards atelectasis between different patient groups one month after completion of treatment.
Atelectasis as regards radiology Group I (%) Group II (%) Group III (%) P value
(I) Patients with atelectasis before treatment: N (%) 6/11 (54.55) 9/11 (81.82) 14/18 (77.78) >0.05
1. Complete disappearance 3/6 (50) 3/9 (33.33) 3/14 (21.43)
2. Partial disappearance 3/6 (50) 4/9 (44.44) 6/14 (42.86)
3. No change 0 2/9 (22.22) 3/14 (21.43)
4. Progression 0 0 2/14 (14.29)
(II) Patients without atelectasis before treatment: N (%) 5/11 (45.45) 2/11 (18.18) 4/18 (22.22) >0.05
1. Prevention 5/5 (100) 1/2 (50) 3/4 (75)
2. Progression 0 1/2 (50) 1/4 (25)
178 S.M. Shehata et al.improvement of symptoms after electrocautery was
42.9%± 8.6 for dyspnea, 78.5%± 10.6 for haemoptysis,
and 61.5%± 8.9 for cough. Langendijk et al. [12] found that
among patients allocated to receive XRT alone, the response
rate for dyspnea was 37% (16 out of 43). For cough, the re-
sponse rate was 38%, for haemoptysis the response rates was
82%, for chest pain the response rate was 67% and the re-
sponse rate for pain in the arm/shoulder was 69%.
This difference in the response rate may be due to either pa-
tient factors (older age group, poorer performance status), tu-
mor factors (different tumor pathology or stage) and lastly due
to different bronchoscopic techniques used (rigid bronchos-
copy, other endobronchial modality used e.g. laser therapy).
As regards obstruction scores of main and lobar bronchi,
Table 2 showed that there was no signiﬁcant difference be-
tween all patient groups as regards mean obstruction scores
of either main or lobar bronchi one month after completion
of treatment. Group II showed signiﬁcant difference in mean
obstruction scores of main bronchi only, pre-treatment and
one month after completion of treatment. Groups I and III
showed signiﬁcant difference in mean obstruction scores of lo-
bar bronchi only, pre-treatment and one month after comple-
tion of treatment.
Concomitant bronchoscopic electrocautery during XRT
provides higher response rates for re-opening of obstructed air-
way mainly when obstructing tumours present in the main
bronchus.
Mallick et al. [5] demonstrated that there was considerable
improvement in the obstruction score across all patient groups
(combined XRT + bronchoscopic therapy and bronchoscopictherapy alone). This reduction was highly signiﬁcant statisti-
cally (p< 0.001).
In our study, Table 3 illustrated that higher rates of radio-
logical re-expansion assessed with chest radiograph and CT
scan of the chest were observed with XRT and bronchoscopic
therapy compared to bronchoscopic therapy or XRT alone.
Bronchoscopic therapy debulked only endobronchial mass,
while XRT reduced the volume of intrathoracic mass either
(endobronchial or extrabronchial), so both modalities were
complementary to each other and not alternatives.
Langendijk et al. [12] demonstrated that signiﬁcantly higher
rates of radiological re-expansion assessed with chest radio-
graph and CT scan of the chest were observed with XRT
and electrocautary compared to XRT alone.
As regards changes in pulmonary function tests; Table 4
showed that patients in Group I were signiﬁcantly better than
Groups II and III as regards changes in FVC after one week of
treatment. After one month of treatment there were signiﬁcant
improvements in patients of Group I than in both Groups II
and III as regards changes in FVC% and FEV1%. Broncho-
scopic treatment enabled rapid mechanical debulking of
obstructing mass and hence immediate relief of atelectasis
and re-expansion of previously collapsed lung so causing
improvement of pulmonary functions.
XRT showed a delayed relief of pulmonary functions, as it
needed at least four weeks to allow enough time for acute mor-
bidity to subside and the re-expansion of collapsed lung to be
evident.
Stout et al. [10] stated that XRT alone resulted in re-inﬂa-
tion of collapsed lung and improvement of pulmonary
Table 4 Comparison between different patient groups according to pulmonary function tests pre-treatment, one week and one month
after completion of treatment.
Pulmonary function tests Group I Group II Group III P value
(I) FEV1% (mean ± SD)
Pre-treatment 58 ± 14.29 51.18 ± 13.49 56.28 ± 12.32 >0.05
Post-one week treatment 69.55 ± 10.37a 63.91 ± 11.75 57.78 ± 13.93 <0.05
Post-one month treatment 76.64 ± 9.8b 64 ± 12.13 63.56 ± 16.8 <0.05
P1 value <0.001 <0.05 >0.05
P2 value <0.001 <0.05 <0.05
(I) FVC% (mean ± SD)
Pre-treatment 67.64 ± 11.28 61.82 ± 10.40 65.89 ± 8.08 >0.05
Post-one week treatment 77.45 ± 6.15a 69.45 ± 8.63 67.94 ± 11.7 <0.05
Post-one month treatment 83.55 ± 6.41b 70.09 ± 9.14 70.72 ± 12.92 <0.01
P1 value <0.001 <0.05 >0.05
P2 value <0.001 <0.05 <0.05
P1: means probability of difference between pre-treatment and one week post-treatment.
P2: means probability of difference between pre-treatment and one month post-treatment.
One week after completion of treatment: Group I was signiﬁcantly better than both Groups II & III as regards changes in FVC%.
One month after completion of treatment: Group I was signiﬁcantly better than Groups II and III as regards changes in FEV1 and FVC.
a Means Group I was signiﬁcantly different than Group III only.
b Means Group I was signiﬁcantly different than Groups II and III.
Outcome of endobronchial electrocautery versus external beam radiotherapy 179function tests 60%. Hossni et al. [11] demonstrated that
improvement of pulmonary function tests (PFT) after bron-
choscopic electrocautery treatment were FVC 15.8%± 6.6
and FEV1 12.6%± 4.9.
As regards changes in PaO2 Table 5 showed that:
One week after completion of treatment: Group I was sig-
niﬁcantly different than Group II and III as regards changes
in PaO2. But, both Groups I and II showed signiﬁcant differ-
ence as regards changes in PaO2, pre-treatment and one week
after completion of treatment. Group III showed no signiﬁcant
difference as regards changes in PaO2, pre-treatment and one
week after completion of treatment.
One month after completion of treatment: Group I was sig-
niﬁcantly different than Groups II and III as regards changes
in PaO2. All patient groups showed signiﬁcant difference as re-
gards changes in PaO2, pre-treatment and one month after
completion of treatment.
Venuta et al. [13] showed that PaO2 signiﬁcantly improved
after laser bronchoscopic treatment (69 ± 8 mmHg pre laser,
82 ± 5 mmHg post laser, P< 0.001).
Quality of life assessment demonstrated that:
One week after treatment completion, both Groups I and II
showed statistically signiﬁcant improvement in the global
health status, the symptom scales of dyspnea, cough,Table 5 Comparison between different patient groups according to P
treatment.
PaO2 (mmHg) Group I
Pre-treatment 75.36 ± 8.55
Post-one week treatment 83.18 ± 6.93a
Post-one month treatment 85.18 ± 7.13a
P1 value <0.001
P2 value <0.001
P1: means probability of difference between pre-treatment and Post-one
P2: means probability of difference between pre-treatment and Post-one
a Means Group I was signiﬁcantly different than Groups II and III.haemoptysis and insomnia. Most of the functional scales
(physical, role, cognitive and emotional functioning) also
showed signiﬁcant improvement. On the other hand, Group
III showed only signiﬁcant improvement in nausea and vomit-
ing, constipation symptom scales and (emotional and cogni-
tive) functional scales. Bronchoscopic electrocautery showed
immediate relief of endobronchial symptoms mainly, while
XRT alone did not.
One month after treatment completion, all patient groups
showed statistically signiﬁcant improvement in the global
health status, the symptom scales of dyspnea, cough, haemopt-
ysis, anorexia and insomnia. Most of the functional scales
(physical, role, cognitive and emotional functioning) also
showed signiﬁcant improvement. On the other hand, Groups
I and III showed signiﬁcant improvement in fatigue, pain in
(chest, arms/shoulders) and medicine for pain. XRT had ten-
dency to palliate chest pain and the more systemic symptoms
of anorexia, tiredness and nausea. Also, XRT relieved the
endobronchial symptoms but with delayed effect. In contrary,
bronchoscopic electrocautery were ineffective in palliation of
extrabronchial symptoms and other systemic symptoms as
they have no effect on extraluminal masses or pathology of tu-
mor. Thus, XRT and bronchoscopic therapy may well perform
complimentary roles in palliation.aO2 pre-treatment, one week and one month after completion of
Group II Group III P value
70.18 ± 7.55 72.28 ± 5.51 >0.05
75.36 ± 5.77 74.50 ± 8.23 <0.01
76.18 ± 5.11 77.38 ± 6.3 <0.01
<0.05 >0.05
<0.01 <0.05
week treatment.
month treatment.
180 S.M. Shehata et al.Venuta et al. [13] demonstrated that the functional scales
(physical, emotional and social) and the symptoms scales (fati-
gue, dyspnea and pain) were signiﬁcantly improved after endo-
scopic treatment, as well as the global quality of life scaleTable 6 Comparison between different patient groups according to
Complications Group I (%)
1.No complications 5(45.5)
2. Hemoptysis No. (%) 0
3.Pneumothorax No. (%) 1(9.1)
4.Oesophagitis No. (%) 3(27.3)
5.Pneumonitis No. (%) 0
6. Skin reactions No. (%) 2(18.2)
a Means Group II was signiﬁcantly different than Groups I and III.
Table 7 Comparison between different patient groups according
status and Functional scales) pre-treatment, one week and one mon
EORTC QLQ-C30 Group I
(I) Global health status 50.65 ± 15.14
Pre-treatment 81.82 ± 9.63
One week post-treatment 89.66 ± 9.63
One month post-treatment
P1 value <0.001
P2 value <0.001
(II) Functional scales
1. Physical functioning
Pre-treatment 74.09 ± 14.8
One week post-treatment 42.27 ± 9.58
One month post-treatment 32.73 ± 6.84
P1 value <0.001
P2 value <0.001
2. Role functioning
Pre-treatment 76.14 ± 16.25
One week post-treatment 43.18 ± 10.25
One month post-treatment 34.09 ± 5.84
P1 value <0.001
P2 value <0.001
3. Emotional functioning
Pre-treatment 69.89 ± 13.35
One week post-treatment 40.34 ± 11.98
One month post-treatment 40.34 ± 11.98
P1 value <0.001
P2 value <0.001
4. Cognitive functioning
Pre-treatment 81.36 ± 25.28
One week post-treatment 69.55 ± 8.43
One month post-treatment 69.55 ± 8.43
P1 value >0.05
P2 value >0.05
5. Social functioning
Pre-treatment 76.82 ± 21.19
One week post-treatment 69.55 ± 11.56
One month post-treatment 69.55 ± 11.56
P1 value >0.05
P2 value >0.05
P1: means probability of difference between pre-treatment and Post-one
P2: means probability of difference between pre-treatment and Post-one
a Means Group III was signiﬁcantly different than Groups I and II.(p-value <0.001). Mallick et al. [5] found that one month after
treatment completion, there was improvement in most catego-
ries that were relevant to the patient population and the treat-
ment received. The global health status was signiﬁcantlypost treatment complications.
Group II Group III (%) P-value
11(100%)a 10(55.6) <0.05
0 1(5.6) –
0 0 –
0 6(33.3) >0.05
0 1(5.6) –
0 0 –
to quality of life outcomes (EORTC QLQ-C30) (Global health
th after completion of treatment.
Group II Group III P-value
57.79 ± 19.81 60.32 ± 15.34 >0.05
85.71 ± 18.35 60.32 ± 15.34a <0.01
84.42 ± 22.32 73.02 ± 26.22 >0.05
<0.01 >0.05
<0.01 <0.05
64.09 ± 25.87 74.09 ± 14.8 >0.05
41.36 ± 15.51 70.44 ± 25.55a <0.05
39.09 ± 13.93 53.82 ± 27.87a <0.05
<0.01 >0.05
<0.001 <0.001
82.95 ± 17.02 71.53 ± 16.5 >0.05
54.55 ± 14 68.39 ± 20.96a <0.001
48.86 ± 18.07 48.61 ± 24.59 >0.05
<0.001 >0.05
<0.001 <0.001
78.41 ± 14.89 73.26 ± 12.46 >0.05
47.16 ± 12.61 53.13 ± 15.93 >0.05
47.16 ± 12.61 53.13 ± 15.93 >0.05
<0.001 <0.001
<0.001 <0.001
86.36 ± 14.2 87.5 ± 7.43 >0.05
74.32 ± 10.25 71.25 ± 17.81 >0.05
74.32 ± 10.25 71.25 ± 17.81 >0.05
<0.05 <0.001
<0.05 <0.001
84.09 ± 15.9 81.94 ± 13.71 >0.05
78.55 ± 15.08 77 ± 19.17 >0.05
78.55 ± 15.08 77 ± 19.17 >0.05
>0.05 >0.05
>0.05 >0.05
week treatment.
month treatment.
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improvement in the symptom scales of dyspnea, cough, haem-
optysis and fatigue. Most of the functional scales (physical
functioning, role functioning and social functioning) also
showed signiﬁcant improvement. Other parameters that had
initially near-normal scores were maintained.
Complications were recorded during treatment and during
a follow-up period of one month after completion of treat-
ment, Table 6 showed that no complications were occurred
in Group II patients. In Group I, 55.5% of patients developed
complications in the form of {pneumothorax, grade II oesoph-
agitis and skin reactions}. Lastly, in Group III, 44.4% of pa-
tients developed complications in the form of {grade II
oesophagitis, mild hemoptysis in one patient and grade II
pneumonitis}. Bronchoscopic electrocautery is less compli-
cated procedure than XRT.
A tracheal ﬁre while using bronchoscopic electrocautery
was reported by Hooper and Jackson [14] and may have con-
tributed to the unpopularity of electrocautery. Stout et al. [10]
stated that the excess acute morbidity (dysphagia) with XRT
was expected and reached statistical signiﬁcance in the clini-
cians’ assessment. Crosta et al. [1] demonstrated that no lethal
complications such as hemorrhage, pneumothorax, respiratory
and heart failure, myocardial infarction and pulmonary embo-
lism that have been observed in their treated patients. Hosni
et al. [11] stated that complications encountered from electro-
cautery were negligible. Bleeding in 3 (4%) patients, Pneumo-
mediastinum in 1 (1%) patients, Hypercarbia in 1 (1%)
patients and no complication in 10 (13.3%) patients. Mallick
et al. [5] stated that the radiotherapy-related morbidity was
low. Acute grade I odynophagia was seen in 32 of the 95 pa-
tients (33.7%) patients. All acute complications were self-lim-
iting. No grade II-grade IV acute complications were seen.
This variations in the results of post-treatment complications
may be due to advanced patient age; presence of associated
comorbidities, poor performance status, less preoperative pul-
monary reserve or may be due to different bronchoscopic pro-
cedures used using rigid bronchoscope or different sedations
during general anesthesia or different XRT fractionation dose
applied (Table 7).
Finally, bronchoscopic therapeutic procedures are safe and
effective tools for immediate endobronchial symptom pallia-
tion in advanced NSCLC. It considerably improves the quality
of life in advanced NSCLC.
The beneﬁt with XRT was seen mainly in chest pain, anor-
exia, nausea and tiredness. These are mainly extrabronchial
symptoms, and cannot be palliated with bronchoscopic elec-
trocautery. Thus, XRT and bronchoscopic therapy may well
perform complimentary roles in palliation.
Conclusion
The replacement of external radiation with bronchoscopic
therapy may not be a recommended option, but its addition
to XRT may be a relatively simple method of augmenting
the symptom palliative effect, providing higher response rates
for re-expansion of collapsed lung and reducing endobronchial
obstruction endoscopically. We recommend a long-term, large
number prospective study of various therapeutic broncho-scopic modalities, to assess survival and quality of life of pa-
tients with NSCLC for long duration, and also the possible
recurrence rate of the lesions.References
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